SKNY — LIR Life Sciences Cashflow Statement
0.000.00%
Last trade - 00:00- CA$3.73m
- CA$3.53m
Annual cashflow statement for LIR Life Sciences, fiscal year end - April 30th, CAD millions except per share, conversion factor applied.
2021 January 31st | 2022 January 31st | 2024 April 30th | 2025 April 30th | 2026 April 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 15 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.006 | -0.093 | -4.34 | -7.36 | -3.9 |
| Amortisation | |||||
| Non-Cash Items | — | — | 1.06 | 6.42 | 2.02 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.002 | 0.044 | 0.157 | 0.334 | -0.168 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -0.004 | -0.049 | -3.12 | -0.602 | -2.04 |
| Capital Expenditures | 0 | -0.071 | -1.75 | -0.489 | -0.105 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | — | -0.05 | — | 1.52 |
| Sale of Business | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 0 | -0.071 | -1.8 | -0.489 | 1.41 |
| Financing Cash Flow Items | — | — | -0.333 | -0.004 | -0.003 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.516 | 0.054 | 5.86 | -0.004 | 1.1 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.512 | -0.066 | 0.941 | -1.1 | 0.476 |